Skip to content

Study on the effect of intraoperative hyperlactatemia on early allograft dysfunction in liver transplantation

Study on the effect of intraoperative hyperlactatemia on early allograft dysfunction in liver transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111738
Enrollment
Unknown
Registered
2025-11-05
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Allograft Dysfunction after Liver Transplantation

Interventions

Pathological Hyperlactatemia Group:None
Physiological Hyperlactatemia Group:None

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 - 70 years who underwent allogeneic liver transplantation; 2. Intraoperative lactate levels were monitored (including data at least at three time points: at the time of skin incision, 30 minutes after portal vein reperfusion, and at the end of surgery) 3. Postoperative follow - up time >= 7 days, with complete evaluation indicators for early allograft dysfunction (EAD) (such as bilirubin, INR, ALT/AST, etc. from 1 to 7 days after surgery) 4. Informed consent was signed by the patient or their authorized family members (for retrospective studies, the conditions for waiver of informed consent in line with ethical requirements must be met

Exclusion criteria

Exclusion criteria: 1. Preoperative presence of severe lactic acid metabolism disorders (such as congenital lactic acidosis, mitochondrial diseases); 2. Preoperative presence of severe lactic acid metabolism disorders (such as congenital lactic acidosis, mitochondrial diseases);? Concurrent combined transplantation of other organs during liver transplantation (such as liver - kidney combined transplantation); 3. Death during surgery or within 24 hours after surgery; 4. Incomplete clinical data or samples; 5. Preoperative presence of severe infections or autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
Early Allograft Dysfunction after Liver Transplantation;Lactic acid;Liver Function;

Secondary

MeasureTime frame
Complete Blood Count;Renal Function;Postoperative Complication;ICU Length of Stay;Inflammatory Factor;Lactylation;Ferroptosis;30-Day Postoperative Mortality;

Countries

China

Contacts

Public ContactXiaolian Nong

The First Affiliated Hospital of Guangxi Medical University

648557176@qq.com+86 182 7718 8692

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026